Cyclo Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2012 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Cyclo Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2012 to Q2 2024.
  • Cyclo Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$5.98M, a 29% decline year-over-year.
  • Cyclo Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$20.7M, a 9.9% decline year-over-year.
  • Cyclo Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$20.1M, a 29.8% decline from 2022.
  • Cyclo Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$15.5M, a 8.15% decline from 2021.
  • Cyclo Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$14.3M, a 59.8% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$20.7M -$5.98M -$1.34M -29% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$19.4M -$4.34M +$664K +13.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$20.1M -$5.64M -$662K -13.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-18
Q3 2023 -$19.4M -$4.77M -$524K -12.4% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 -$18.9M -$4.64M -$1.18M -34.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$17.7M -$5.01M -$2.24M -80.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$15.5M -$4.98M -$2.19M -78.4% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-18
Q3 2022 -$13.3M -$4.25M -$387K -10% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$12.9M -$3.45M +$145K +4.04% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$13M -$2.77M +$1.27M +31.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 -$14.3M -$2.79M -$113K -4.21% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-17
Q3 2021 -$14.2M -$3.86M -$2.42M -169% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$11.7M -$3.6M -$1.41M -64.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-10
Q1 2021 -$10.3M -$4.04M -$1.4M -53.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-10
Q4 2020 -$8.94M -$2.68M -$44.6K -1.69% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-11
Q3 2020 -$8.9M -$1.44M +$190K +11.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$9.09M -$2.19M -$824K -60.3% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-15
Q1 2020 -$8.26M -$2.63M -$730K -38.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-15
Q4 2019 -$7.53M -$2.64M -$1.27M -93% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-12
Q3 2019 -$6.26M -$1.63M -$838K -106% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$5.43M -$1.37M -$78.8K -6.11% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-12
Q1 2019 -$5.35M -$1.9M -$1.09M -134% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-12
Q4 2018 -$4.26M -$1.37M +$18.5K +1.34% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-30
Q3 2018 -$4.27M -$787K -$154K -24.2% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$4.12M -$1.29M -$461K -55.7% Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-14
Q1 2018 -$3.66M -$813K +$175K +17.7% Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-14
Q4 2017 -$3.83M -$1.38M -$552K -66.4% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-15
Q3 2017 -$3.28M -$634K +$981K +60.8% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 -$4.26M -$828K +$243K +22.7% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
Q1 2017 -$4.51M -$987K -$282K -39.9% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-15
Q4 2016 -$4.22M -$832K +$223K +21.2% Oct 1, 2016 Dec 31, 2016 10-K 2018-04-16
Q3 2016 -$4.45M -$1.61M -$867K -116% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 -$3.58M -$1.07M -$711K -197% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-11
Q1 2016 -$2.87M -$706K -$318K -81.8% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-12
Q4 2015 -$2.55M -$1.06M -$738K -233% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-17
Q3 2015 -$1.81M -$748K -$527K -238% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-10
Q2 2015 -$1.29M -$360K -$209K -138% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-12
Q1 2015 -$1.08M -$388K -$485K -501% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-16
Q4 2014 -$593K -$317K -$233K -276% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-30
Q3 2014 -$360K -$221K -$126K -134% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-12
Q2 2014 -$233K -$151K -$415K -157% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-14
Q1 2014 $182K $96.9K -$23.2K -19.3% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-15
Q4 2013 $205K -$84.4K -$215K -165% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-27
Q3 2013 $420K -$94.5K -$48.8K -107% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-14
Q2 2013 $469K $264K +$320K Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-14
Q1 2013 $149K $120K +$74.3K +162% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-09
Q4 2012 $74.2K $131K Oct 1, 2012 Dec 31, 2012 10-K 2014-03-04
Q3 2012 -$45.7K Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-13
Q2 2012 -$56.4K Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-14
Q1 2012 $45.8K Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.